A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years
Abstract Background Although migraine is a disabling neurological condition that causes important disability, it remains an area of underdiagnosis and undertreatment worldwide. The aim of this study was to depict the burden of the unmet medical needs in migraine treated with triptans in a large Ital...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-06-01
|
| Series: | The Journal of Headache and Pain |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s10194-019-1027-7 |
| _version_ | 1818259595395596288 |
|---|---|
| author | Carlo Piccinni Sabina Cevoli Giulia Ronconi Letizia Dondi Silvia Calabria Antonella Pedrini Immacolata Esposito Valentina Favoni Giulia Pierangeli Pietro Cortelli Nello Martini |
| author_facet | Carlo Piccinni Sabina Cevoli Giulia Ronconi Letizia Dondi Silvia Calabria Antonella Pedrini Immacolata Esposito Valentina Favoni Giulia Pierangeli Pietro Cortelli Nello Martini |
| author_sort | Carlo Piccinni |
| collection | DOAJ |
| description | Abstract Background Although migraine is a disabling neurological condition that causes important disability, it remains an area of underdiagnosis and undertreatment worldwide. The aim of this study was to depict the burden of the unmet medical needs in migraine treated with triptans in a large Italian population. Methods A 2-year longitudinal analysis of migraineurs with unmet medical needs on treatment with triptans was performed. The studied cohort consisted of subjects with ≥4 triptan dose units per month, selected from the general population These patients were stratified into: possible Low-Frequency Episodic Migraine (pLF-EM: 4–9 triptan dose units per month), possible High-Frequency Episodic Migraine (pHF-EM: 10–14 triptan dose units per month) and possible Chronic Migraine (pCM:> 14 triptan dose units per month). The first follow-up year was analysed to describe the use of preventive therapies, the second year to describe the ≥50% reduction in triptan use. Results Of 10,270,683 adults, 8.0 per 1000 were triptan users and, of these, 38.2% were migraineurs with unmet medical needs, corresponding to 3.1 per 1000 adults. By stratifying for the number of triptan dose units per month, 72.3% were affected by pLF-EM, 17.4% by pHF-EM, and 10.3% by pCM. In this cohort, 19.1% of individuals used oral preventive drugs and 0.1% botulinum toxin. Triptan use reduction was found in 22.3% individuals of the cohort, decreasing with the intensification of need levels (25.8% pLF-EM, 13.6% pHF-EM, 12.0% pCM). Conclusions This real-life analysis underlined that the unmet medical needs concern a large part of patients treated with triptans and there is an undertreatment with preventive therapies whose benefit is insufficient, which may be due to the lack of effective preventive strategies, probably still reserved to severe patients. This study allows forecasting the actual impact of newest therapeutic strategies aimed to fill this gap. |
| first_indexed | 2024-12-12T18:17:56Z |
| format | Article |
| id | doaj.art-fc916f3ce984498da82098134079296c |
| institution | Directory Open Access Journal |
| issn | 1129-2369 1129-2377 |
| language | English |
| last_indexed | 2024-12-12T18:17:56Z |
| publishDate | 2019-06-01 |
| publisher | BMC |
| record_format | Article |
| series | The Journal of Headache and Pain |
| spelling | doaj.art-fc916f3ce984498da82098134079296c2022-12-22T00:16:14ZengBMCThe Journal of Headache and Pain1129-23691129-23772019-06-012011910.1186/s10194-019-1027-7A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two yearsCarlo Piccinni0Sabina Cevoli1Giulia Ronconi2Letizia Dondi3Silvia Calabria4Antonella Pedrini5Immacolata Esposito6Valentina Favoni7Giulia Pierangeli8Pietro Cortelli9Nello Martini10Fondazione ReS (Ricerca e Salute) – Research and Health FoundationIRCCS Istituto delle Scienze Neurologiche di BolognaFondazione ReS (Ricerca e Salute) – Research and Health FoundationFondazione ReS (Ricerca e Salute) – Research and Health FoundationFondazione ReS (Ricerca e Salute) – Research and Health FoundationFondazione ReS (Ricerca e Salute) – Research and Health FoundationDrugs and HealthIRCCS Istituto delle Scienze Neurologiche di BolognaIRCCS Istituto delle Scienze Neurologiche di BolognaIRCCS Istituto delle Scienze Neurologiche di BolognaFondazione ReS (Ricerca e Salute) – Research and Health FoundationAbstract Background Although migraine is a disabling neurological condition that causes important disability, it remains an area of underdiagnosis and undertreatment worldwide. The aim of this study was to depict the burden of the unmet medical needs in migraine treated with triptans in a large Italian population. Methods A 2-year longitudinal analysis of migraineurs with unmet medical needs on treatment with triptans was performed. The studied cohort consisted of subjects with ≥4 triptan dose units per month, selected from the general population These patients were stratified into: possible Low-Frequency Episodic Migraine (pLF-EM: 4–9 triptan dose units per month), possible High-Frequency Episodic Migraine (pHF-EM: 10–14 triptan dose units per month) and possible Chronic Migraine (pCM:> 14 triptan dose units per month). The first follow-up year was analysed to describe the use of preventive therapies, the second year to describe the ≥50% reduction in triptan use. Results Of 10,270,683 adults, 8.0 per 1000 were triptan users and, of these, 38.2% were migraineurs with unmet medical needs, corresponding to 3.1 per 1000 adults. By stratifying for the number of triptan dose units per month, 72.3% were affected by pLF-EM, 17.4% by pHF-EM, and 10.3% by pCM. In this cohort, 19.1% of individuals used oral preventive drugs and 0.1% botulinum toxin. Triptan use reduction was found in 22.3% individuals of the cohort, decreasing with the intensification of need levels (25.8% pLF-EM, 13.6% pHF-EM, 12.0% pCM). Conclusions This real-life analysis underlined that the unmet medical needs concern a large part of patients treated with triptans and there is an undertreatment with preventive therapies whose benefit is insufficient, which may be due to the lack of effective preventive strategies, probably still reserved to severe patients. This study allows forecasting the actual impact of newest therapeutic strategies aimed to fill this gap.http://link.springer.com/article/10.1186/s10194-019-1027-7Real-world evidenceBurden of diseaseItalyAdministrative databasesObservational studyPharmacoepidemiology |
| spellingShingle | Carlo Piccinni Sabina Cevoli Giulia Ronconi Letizia Dondi Silvia Calabria Antonella Pedrini Immacolata Esposito Valentina Favoni Giulia Pierangeli Pietro Cortelli Nello Martini A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years The Journal of Headache and Pain Real-world evidence Burden of disease Italy Administrative databases Observational study Pharmacoepidemiology |
| title | A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years |
| title_full | A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years |
| title_fullStr | A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years |
| title_full_unstemmed | A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years |
| title_short | A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years |
| title_sort | real world study on unmet medical needs in triptan treated migraine prevalence preventive therapies and triptan use modification from a large italian population along two years |
| topic | Real-world evidence Burden of disease Italy Administrative databases Observational study Pharmacoepidemiology |
| url | http://link.springer.com/article/10.1186/s10194-019-1027-7 |
| work_keys_str_mv | AT carlopiccinni arealworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT sabinacevoli arealworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT giuliaronconi arealworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT letiziadondi arealworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT silviacalabria arealworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT antonellapedrini arealworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT immacolataesposito arealworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT valentinafavoni arealworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT giuliapierangeli arealworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT pietrocortelli arealworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT nellomartini arealworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT carlopiccinni realworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT sabinacevoli realworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT giuliaronconi realworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT letiziadondi realworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT silviacalabria realworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT antonellapedrini realworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT immacolataesposito realworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT valentinafavoni realworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT giuliapierangeli realworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT pietrocortelli realworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears AT nellomartini realworldstudyonunmetmedicalneedsintriptantreatedmigraineprevalencepreventivetherapiesandtriptanusemodificationfromalargeitalianpopulationalongtwoyears |